

DAFTAR PUSTAKA

- Bamberger DM. 2010. Diagnosis, Initial Management, And Prevention Of Meningitis. *Am Fam Physician*, 82(12): 1491-1498.
- Bisht, R., Katiyar, A., Singh, R., Mittal, P., 2009. Antibiotic Resistance -A Global Issue of Concern. *Asian Journal of Pharmaceutical and Clinical Research*, Vol 2 Issue 2, pp. 34-39.
- Brouwer MC, Tunkel AR, van de Beek D. 2010. Epidemiology, Diagnosis, and Antimicrobial Treatment of Acute Bacterial Meningitis. *Clin Biol Rev*, 23(3): 467–492.
- Campbell EA, Korzheva N, Mustaev A, Murakami K., 2001. Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase. *Cell*, 104(6): p. 901-912.
- Center for Disease Control and Prevention. *Bacterial meningitis*. Dikutip pada tanggal 29 Januari 2021, pada <https://www.cdc.gov/meningitis/bacterial.html>.
- Chadick DR. 2005. Viral meningitis. *British Medical Bulletin*, 75:1-14.
- Dian, S., Yunivita, V., Ganiem, A. R., Pramaesya, T., Chaidir, L., Wahyudi, K., Aarnoutse, R. 2018. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin For Tuberculous Meningitis. *Antimicrobial Agents and Chemotherapy*, 62(12).
- Ding, J., Thuy Thuong Thuong, N., Pham, T. V., Heemskerk, D., Pouplin, T., Tran, C. T. H., Tarning, J. 2020. Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. *Clinical Pharmacology and Therapeutics*, 107(4), 1023–1033.
- Elyasi, S., Khalili, H., Dashti-Khavidaki, S., & Emadi-Koochak, H. 2015. Conventional- Versus High-Dose Vancomycin Regimen In Patients With Acute Bacterial Meningitis: A Randomized Clinical Trial. *Expert Opinion on Pharmacotherapy*, 16(3), 297–304.
- Hasbun R. 2018. Meningitis. *Medscape*. Dikutip pada tanggal 29 Januari 2021, pada <https://emedicine.medscape.com/article/232915-overview>.
- Heemskerk, D., Day, J., Chau, T. T. H., Dung, N. H., Yen, N. T. B., Bang, N. D., Farrar, J. 2011. Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): Protocol for a randomized controlled trial. *Trials*, 12.
- Heemskerk, A. D., Bang, N. D., Mai, N. T. H., Chau, T. T. H., Phu, N. H., Loc, P. P., Farrar, J. J. 2016. Intensified Antituberculosis Therapy in Adults with Tuberculous Meningitis. *New England Journal of Medicine*, 374(2), 124–134

- Heemskerk, A. D., Nguyen, M. T. H., Dang, H. T. M., Vinh Nguyen, C. V., Nguyen, L. H., Do, T. D. A., Thwaites, G. E. 2017. Clinical Outcomes of Patients with Drug-Resistant Tuberculous Meningitis Treated with an Intensified Antituberculosis Regimen. *Clinical Infectious Diseases*, 65(1), 20–28.
- Hoffman O, Weber RJ. 2009. Pathophysiology And Treatment Of Bacterial Meningitis. *Ther Adv Neurol Disord*, 2(6):1-7.
- H. Rifiana Onassis., 2018. **Panduan pola Kuman dan Antimikroba 2018**. Surabaya: Rumah Sakit Angkatan Laut Dr. Ramelan.
- Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta ZA, Abramson J. 2013. Global Epidemiology Of Invasive Meningococcal Disease. *Popul Health Metr*, 11(1):17.
- Kalita, J., Misra, U. K., Prasad, S., & Bhoi, S. K. 2014. Safety And Efficacy Of Levofloxacin Versus Rifampicin In Tuberculous Meningitis: An Open-Label Randomized Controlled Trial. *Journal of Antimicrobial Chemotherapy*, 69(8), 2246–2251.
- Kalita, J., Bhoi, S. K., Betail, S., & Misra, U. K. 2016. Safety And Efficacy Of Additional Levofloxacin In Tuberculous Meningitis: A Randomized Controlled Pilot Study. *Tuberculosis*, 98, 1–6.
- Kementrian Kesehatan RI. 2011. Peraturan Menteri Kesehatan Republik Indonesia Nomor : 2406/MENKES/PER/XII/2011 tentang **Pedoman Umum Penggunaan Antibiotik**. Jakarta: Menteri Kesehatan RI.
- King DE, Malone R, Lilley SH. 2000. **New Classification and Update on the Quinolone Antibiotics**. Dikutip pada tanggal 29 Januari 2021, pada <http://www.aafp.org/afp/2000/0501/p2741.html>.
- Kurniawati A. 2013. **Pola Penggunaan Antibiotik pada Pasien Meningitis di Instalasi Rawat Inap RSUD Dr. Soetomo Surabaya**. Surabaya: RSUD Dr. Soetomo.
- Leekha, S., Terrell, C.L., Edson, R.S., 2011. General Principles Of Antimicrobial Therapy. *Symposium On Antimicrobial Therapy*, pp. 156-167.
- Lu, C., Zhang, Y., Chen, M., Zhong, P., Chen, Y., Yu, J., Zhang, J. 2016. Population Pharmacokinetics And Dosing Regimen Optimization Of Meropenem In Cerebrospinal Fluid And Plasma In Patients With Meningitis After Neurosurgery. *Antimicrobial Agents and Chemotherapy*, 60(11), 6619–6625.
- Manolio TA, Bailey-Wilson JE, Collins FS. 2006. Genes, Environment And The Value Of Prospective Cohort Studies. *Nat. Rev. Genet*, 7(10): 812–20.

- Maimaiti, N., Zafar, A., Amrizal, M., Zaleha, M. I., Saperi, S., & Aljunid, S. 2012. Estimating Clinical And Economic Burden Of Pneumococcal Meningitis In Malaysia Using Casemix Data. *BMC Health Services Research*, 12(1).
- Morita, A., Kamei, S., Minami, M., Yoshida, K., Kawabata, S., Kuroda, H., Iwata, S. 2014. Open-Label Study To Evaluate The Pharmacodynamics, Clinical Efficacy, And Safety Of Meropenem For Adult Bacterial Meningitis In Japan. *Journal of Infection and Chemotherapy*, 20(9), 535–540.
- National Institute for Health and Care Excellence, 2019. *Randomised Controlled Trial*. Dikutip pada tanggal 29 Januari 2021, pada <https://www.nice.org.uk/glossary>.
- National Institutes of Health. 2020. *Open Label Study*. Dikutip pada tanggal 29 Januari 2021, pada <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/open-label-study>.
- National Organization for Rare Disorders. *Meningitis, Bacterial*. Dikutip pada tanggal 29 Januari 2021, pada <https://www.rarediseases.org/rare-diseases/meningitis-bacterial>.
- Nicholas Young, Mark Thomas. 2018. Meningitis in adults: diagnosis and management. *Internal Medicine Journal* 48 (2018) 1294–1307.
- Oliphant, C.M., 2016. Antimicrobial regiment selection, *Pharmacotherapy Principles & Practice 14th Edition*. Newyork: McGraw Hill Education. Pp. 1033-1047.
- Rumah Sakit Umum Daerah Dr. Soetomo. 2018. *Panduan Penggunaan Antibiotik Profilaksis Dan Terapi*. Surabaya: RSUD Dr. Soetomo.
- Ruslami, R., Ganiem, A. R., Dian, S., Apriani, L., Achmad, T. H., van der Ven, A. J., Van Crevel, R. 2013. Intensified Regimen Containing Rifampicin And Moxifloxacin For Tuberculous Meningitis: An Open-Label, Randomised Controlled Phase 2 Trial. *The Lancet Infectious Diseases*, 13(1), 27–35.
- Te Brake, L., Dian, S., Ganiem, A. R., Ruesen, C., Burger, D., Donders, R., Aarnoutse, R. 2015. Pharmacokinetic/Pharmacodynamic Analysis Of An Intensified Regimen Containing Rifampicin And Moxifloxacin For Tuberculous Meningitis. *International Journal of Antimicrobial Agents*, 45(5), 496–503.
- Tunkel, A. R., Hasbun, R., Bhimraj, A., Byers, K., Kaplan, S. L., Scheld, W. M., Zunt, J. R. 2017. Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. *Clinical Infectious Diseases*, 64(6): p34–65.
- Utami, E.R., 2011. Antibiotika, Resistensi, Dan Rasionalitas Terapi, *El-Hayah.*, Vol. 1 No.4, pp. 191-198.

World Health Organization. 2010. *Treatment Of Tuberculosis: Guidelines Edisi Ke-4*. Geneva: WHO Press.

Yunivita, V., Dian, S., Ganiem, A. R., Hayati, E., Hanggono Achmad, T., Purnama Dewi, A., Ruslami, R., 2016. Pharmacokinetics And Safety/Tolerability Of Higher Oral And Intravenous Doses Of Rifampicin In Adult Tuberculous Meningitis Patients. *International Journal of Antimicrobial Agents*, 48(4), 415–421.

Zhang, Y., Zhang, J., Chen, Y., Yu, J., Cao, G., Wu, X. Zhao, X. 2017. Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery. *World Neurosurgery*, 98, 525–531.